-+ 0.00%
-+ 0.00%
-+ 0.00%

ZAI LAB’S ZOCILURTATUG PELITECAN (ZOCI, FORMERLY ZL-1310) DEMONSTRATES HIGH RESPONSE RATES, ENCOURAGING DURABILITY AND WELL-TOLERATED SAFETY PROFILE IN FIRST-LINE EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Reuters·10/23/2026 10:33:00

Please log in to view news